Background: Lung involvement is one of the major systemic manifestations of primary Sjögren's syndrome (pSS). This study aims to demonstrate the correlation between high-resolution computed tomography (HRCT), pulmonary function test (PFT) results, and outcome in these patients. Methods: Forty-four pSS patients were enrolled and their PFT results and HRCT findings/scores were retrospectively investigated. Results: All patients had reduced carbon monoxide-diffusing capacity (DL CO ; <75% of the predicted value); <60% of the predicted value of peak expiratory flow (PEF), of forced vital capacity (FVC), and of forced expiratory volume in the 1st second (FEV 1 ) were noted in 15 (34.1%) patients, 13 (29.5%) patients, and 12 (27.3%) patients, respectively. HRCT scores had a negative correlation with DL CO (r ¼ À0.376, p ¼ 0.012), but not with other PFT results. Twelve patients (27.3%) expired during a mean follow-up of 3.7 years; 11 (91.7%) patients died of respiratory failure in the lunginvolved patients, of which three were present with pneumonia. The expired patients had lower predicted values of FEV 1 (63.1 AE 19.4% vs. 79.0 AE 22.7%, p ¼ 0.017), FVC (58.7 AE 20.4% vs. 77.1 AE 17.5%, p ¼ 0.005), and PEF (54.3 AE 20.5% vs. 72.0 AE 24.8%, p ¼ 0.035), and higher HRCT scores (9.2 AE 5.7 vs. 5.2 AE 3.5, p ¼ 0.033) than those patients who survived. Patients with FEV 1 , FVC, PEF < 60% of the predicted value, or high HRCT score (13e18) presented shorter median overall survival (p ¼ 0.005, p < 0.001, p ¼ 0.021, p < 0.001, respectively). Multivariate analysis adjusted for PFT results showed that HRCT !13 was an independent risk factor for mortality (p ¼ 0.007). Conclusion: The clinical outcome of pSS patients with lung involvement in Taiwan is not very favorable. Although HRCT score was poorly correlated with PFT, high HRCT score was significantly associated with higher mortality.
Introduction
Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease that predominantly impairs the functioning of the exocrine glands due to focal lymphocytic infiltration and usually presents clinically as persistent dryness of the mouth and eyes. 1 Systemic involvement of the musculoskeletal, cutaneous, pulmonary, gastrointestinal, renal, and/or nervous organs/systems is present in 50e80% of pSS patients. Interstitial lung disease (ILD) and small airway abnormalities are the main pathologic findings in pSS with pulmonary involvement. 2e5 Lung involvement in particular is a very important determinant of the patient's clinical status, quality of life, and outcome.
The frequency of lung involvement in patients with pSS varies, ranging from 9% to 90% in Caucasians. 6, 7 The reasons for this variation remain unclear but may include underdiagnosis due to insignificant symptoms, ethnic, environmental, or genetic factors, or statistical error resulting from limited sample sizes. Chest radiographs, pulmonary function tests (PFTs), and high-resolution computed tomography (HRCT) of the lung are used to investigate the presence and severity of involvement; HRCT is a relatively noninvasive method and is currently the most important way to detect early lung parenchymal abnormalities and decreased lung function. HRCT has been proven to be very sensitive for lung involvement in patients with pSS, even in patients without pulmonary symptoms. 3, 8 Common HRCT findings of pSS in the lungs include ground-glass attenuation, bronchiectasis, a reticular pattern, or a honeycomb appearance. 9, 10 The HRCT scoring method has been used to evaluate lung diseases and is a good predictor of patient outcome. HRCT score has only been described in 14 pSS patients with pulmonary symptoms, but its correlation with outcome has not been previously investigated. 10 The prognosis of patients with pSS is good unless organ involvement manifests. The major causes of mortality of pSS patients are cardiovascular diseases (32.4e52.9%) and hematologic malignancy (17.6e23.5%), which can be either related or unrelated to pSS. 11, 12 However, the influence of lung involvement on the outcomes of patients with pSS have yet to be well elucidated. Ito et al 9 analyzed PFT and HRCT in 33 pSS patients, and found that low partial oxygen pressures and the presence of honeycombing were related to higher mortality. The aim of this study was to determine the clinical characteristics of lung involvement in Taiwanese patients with pSS. Their PFT results, HRCT findings, HRCT scores, and causes of death were recorded. Risk factors for mortality in pSS patients were also investigated.
Methods

Patients
The Taipei Veterans' General Hospital (Taipei, Taiwan) is a 3000-bed acute care hospital that serves as a tertiary referral center. Patients treated at this hospital with a diagnostic code for pSS (ICD-9 710.2) between January 1996 and December 2009 were recruited for this study. All patients satisfied the 2002 AmericaneEuropean Revised Classification Criteria for pSS. 13 To arrive at a definitive diagnosis, it is essential to meet: (1) at least four of six criteria, of which criteria IVand VI are positive; or (2) at least three of the IIIeVI criteria. The criteria are: (I) ocular symptoms of decreased tear production; (II) oral symptoms of decreased saliva production; (III) objective evidence of ocular involvement, Schirmer's test 5 mm/5 minutes, or rose bengal score !4; (IV) salivary gland histopathology with lymphocytes focus score !1; (V) objective evidence of salivary gland involvement (either unstimulated whole salivary flow <1.5 mL in 15 minutes, diffuse sialectasis by parotid sialography, or salivary scintigraphy showing delayed uptake); and (VI) presence of autoantibodies (anti-SSA/Ro, anti-SSB/La, or both). In addition, these illnesses mimicking SS, such as past history of head and neck irradiation treatment or pre-existing lymphoma, hepatitis B or C infection, acquired immunodeficiency disease, sarcoidosis, or graft versus host disease, should be excluded. Patients with other connective tissue diseases that could have induced secondary SS, such as systemic lupus erythematosus, rheumatoid arthritis, polymyositis, dermatomyositis, scleroderma, primary biliary cirrhosis, and mixed connective tissue disease, were excluded. 14 The clinical and immunological profiles, PFT results, and HRCT findings of all patients were analyzed. Forty-four pSS patients were diagnosed as having coexisting lung involvement, defined as the persistence of pulmonary symptoms, such as dyspnea or cough, with coexisting abnormal PFT and/or HRCT findings for longer than 2 weeks. 4, 15 Other medical illnesses that could cause pulmonary manifestations, such as chronic heart failure, infection, hyperthyroidism, arrhythmia, and bronchial asthma, were excluded by clinical assessment and other laboratory investigations, including echocardiographic studies, electrocardiography, and thyroid function tests.
This study was approved by the institutional ethics committee of Taipei Veterans' General Hospital, Taiwan (2013-03-028BC).
PFT and radiologic analysis
Routinely evaluated PFT included forced expiratory volume in the first second (FEV 1 ), forced vital capacity (FVC), carbon monoxide-diffusing capacity (DL CO ), residual volume (RV), and peak expiratory flow (PEF). All HRCT examinations were performed using contiguous axial 5 mm section thickness through the lungs on a Toshiba Aquilion 64 CT scanner (Toshiba, Tokyo, Japan). HRCT findings were read by experienced chest radiologists and categorized according to the classification of CT patterns described by the American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. 16 HRCT scoring was performed according to the definitions reported previously by Schurawitzki et al. 17 Briefly, each of the six lobes of the lung with the lingula counted as a separate lobe was assessed based on the percentage of affected lung parenchyma. Grades were defined as follows: Grade 0, no involvement; Grade 1, involvement up to 25% of a lobe; Grade 2, involvement between 26% and 50% of a lobe; and Grade 3, involvement >50% of a lobe. The HRCT score was obtained by combining grades over all six "lobes", with a possible range of 0e18. The severity of lung involvement was classified according to the HRCT, where 0e6 was defined as mild, 7e12 was defined as moderate, and 13e18 was defined as severe. 10 
Statistical analysis
The goodness-of-fit test, Chi-square test, and/or Fisher's exact test were used to compare categorical variables. Spearman rank correlations were calculated between HRCT scores and PFT values. Overall survival rate was estimated using the KaplaneMeier method, and survival curves were compared using the log-rank test. A p value <0.05 was considered statistically significant. Statistical analyses were performed using SPSS version 15.0 (SPSS Inc., Chicago, IL, USA).
Results
Clinical features and PFT results of patients with pSS with lung involvement
Among our 44 pSS patients with lung involvement (17 male and 27 female), the mean age at diagnosis was 66.5 years (Table  1) . Twelve patients, all of whom were male, had a history of smoking. An antinuclear antibody (ANA) titer of >1:160 was noted in 63.6% of all patients and rheumatoid factor (RF) was positive in 11 of 40 (27.5%) patients. As shown in Tables 1 and 2 , PFT was performed and HRCT scans were obtained from all 44 patients with lung involvement. All patients (44 of 44, 100%) showed restrictive-type results with reduced DL CO (<75% of the predicted value). In addition, 15 (34.1%) patients had PEF results <60% of the predicted value, 13 (29.5%) patients had a reduced FVC, 12 (27.3%) individuals had a reduced FEV 1 , four (9.3%) individuals had a reduced RV, and only one (2.3%) patient had a reduced FEV 1 /FVC (<60% of the predicted value).
HRCT findings
The HRCT features are summarized in Table 3 , and some patterns are shown in Fig. 1 . All scans showed a mixed pattern. The most frequent HRCT finding was interstitial linear opacities (88.6%), followed by interlobular septal thickening (81.8%), and ground-glass opacities (77.3%). The distribution of parenchymal lung involvement was uneven, and was found to be most pronounced in the lower lobes (upper; middle; and lower lobes ¼ 28.6%; 33.3%; and 38.1%, respectively). Analysis of the HRCT scores showed that 20 (45.5%) patients had mild, 17 (38.6%) patients had moderate, and 7 (15.9%) patients had severe lung involvement.
Correlation between HRCT score and PFT results
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Outcome analysis
Twelve (27.3%) of the 44 patients died during the followup period (mean follow-up time, 3.73 years; range, from 2 months to 16 years). The causes of death among the patients with pSS in this study included respiratory failure (n ¼ 8, 66.7%), pneumonia with respiratory failure (n ¼ 3, 25.0%), and sepsis (n ¼ 1, 8.3%). PFT and HRCT scores were compared between those of the 44 patients with lung involvement who died during follow-up and those who survived (Table 4) . Patients who died during follow-up had lower predicted values for FEV 1 KaplaneMeier survival analysis showed that median overall survival was shorter among patients whose FEV 1 value was <60% of the predicted value than those whose FEV 1 value was >60% of the predicted value (p ¼ 0.005; Fig. 3A) . Patients with reduced FVC values (<60% of the predicted value) had shorter median overall survival than those with FVC values >60% of the predicted value (p < 0.001; Fig. 3B) . Similarly, patients with reduced PEF values (<60% of the predicted value) had shorter median overall survival than those with PEF values >60% of the predicted value (p ¼ 0.021; Fig. 3C ). Furthermore, patients with severe lung involvement (high HRCT scores of 13e18) had shorter median overall survival than those with mild or moderate lung involvement (HRCT scores of 0e12; p < 0.001; Fig. 3D ). Multivariate analysis adjusted for FEV 1 , FVC, and PEF, showed that severe lung involvement (HRCT score 13e18) was an independent risk factor for mortality in patients with lung involvement (p ¼ 0.007, odds ratio ¼ 40.154, 95% CI ¼ 2.747e586.991). In addition, being aged > 65 years, sex, and smoking history were not major predictors of mortality in pSS patients with lung involvement.
Discussion
The clinical course of patients with pSS is usually confined to the sicca symptoms unless the extraglandular organs are involved. This study analyzed the clinical characteristics, HRCT findings, and PFT results in pSS patients with lung involvement in Taiwan. Several studies have reported PFT and HRCT findings in pSS patients as summarized in Table 5 . 4, 8, 9, 13, 18, 19 Such HRCT findings in pSS included ground-glass opacities, interstitial linear opacities, interlobular septal thickening, nodules, Fig. 3 . KaplaneMeier survival curves of primary Sjögren's syndrome (pSS) patients with lung involvement. Cumulative overall survival between (A) forced expiratory volume in the first second (FEV 1 ) ! and <60% of the predicted value; (B) forced vital capacity (FVC) ! and <60% of the predicted value; (C) peak and cysts. 3, 4, 10, 18, 19 The reported incidence of these HRCT findings are varied; for example, ground-glass opacities range from 10.8% to 91.7%, interlobular septal thickening range from 24.3% to 55.0%, nodules range from 24.3% to 78.3%, and cysts range from 9.7% to 39.3%. However, the ground-glass opacities pattern seems to be seen less frequently in patients without pulmonary symptom, suggesting that less severe lung involvement goes hand-in-hand with low prevalence of ground-glass opacities. All of our patients presented with lung involvement; the most frequent HRCT findings were interstitial linear opacities (88.6%), interlobular septal thickening (81.8%), groundglass opacities (77.3%), and cysts (72.7%). The discrepancy of the above results could be partially explained by a difference in race, sex distribution, duration of disease, age at examination, and severity of lung injury.
PFT in pSS can be restrictive or obstructive, even in patients without pulmonary symptoms. 4, 8 All of our pSS patients, having been presented with lung involvement, had low DL CO (<75% of predicted vital capacity value), whereas <50% had decreased FEV 1 and FVC (<60% of predicted vital capacity value). As shown in Table 5 , Shi and colleagues 4 reported that PFT results of pSS patients with ILD had a restrictive pattern. Another study determining the PFT results of 33 pSS patients found that over half had restrictive change (<80% of predicted vital capacity value). 9 An obstructive defect of PFT was mainly observed in pSS patients with small airway disease. 2, 4 Compared to these studies, restrictive change was noted in only 8.1% of pSS patients without pulmonary symptoms in the Uffmann et al 8 study, indicating that more serious restrictive-type impairment was noted in pulmonary function of patients with lung involvement than in patients without lung involvement. A limited number of studies focusing on the relationship between HRCT score and PFT have been conducted. Our current study revealed that impairment of DL CO was associated with high HRCT scores. This finding was similar to the report by Yazisiz et al, 10 in which negative correlations between HRCT scores and PFT results were found in 14 Turkish pSS patients with lung involvement. Taking these findings together, we postulated that higher HRCT score is related to more severe lung impairment.
Previous studies have reported that the standardized mortality ratio of patients with pSS is slightly higher than that of age-and sex-matched populations, ranging from 1.17 to 2.07. 11, 12, 20, 21 A prospective cohort study comprising 484 Swedish patients with pSS with a median follow-up time of 7 years showed that the all-cause mortality was no higher in patients with pSS than in the general population. 12 The exact relationship between pulmonary involvement and mortality rate among pSS patients remains to be explored, and more studies should be conducted to further elucidate the connection. Some reports have suggested that pulmonary manifestations of pSS do not worsen the prognosis. A 10-year follow-up of 30 British patients with pSS reported by Davidson et al 22 found that most patents had stable pulmonary function, and mortality was low (15.4%). The mortality rate of our Taiwanese pSS patients with lung involvement was 27.3%, similar to the observation of Ito et al 9 ; in their analysis of 33 Japanese and Korean pSS patients with lung involvement, 10 (30.3%) Uffmann Only this study is performed in pSS patients without pulmonary symptom.
expired. In the study by Davidson et al, 22 four (15.4%) of 26 British patients with pSS died during the 10-year follow-up period: one patient died of respiratory disease (fibrosing alveolitis complicated by bronchopneumonia) and three patients died of cerebrovascular events and cancer. 22 In our study, the most common cause of death was respiratory failure (11 of 12 patients, 91.7%) with or without coexisting pneumonia (n ¼ 3). Taken together, the outcome of pSS with lung involvement in an Asian population seems to be unfavorable.
In addition to exploring the relationship between HRCT score and PFT, our current study demonstrated that the mortality rate was higher in patients with high HRCT scores than those with low HRCT scores in pSS patients with lung involvement. This is the first study to show HRCT to be a good predictor of survival in patients with pSS with lung involvement. A previous study suggested that the presence of microscopic honeycombing was independently associated with mortality. 9 The percentage of patients in our study whose HRCT scans showed a honeycomb pattern was 65.9%, higher than reported in other studies (range, 23.5e42.8%). 3, 10 This may explain why the mortality rate of our patients was higher than other previous reports. Even patients with low FEV 1 , FVC, or PEF presented shorter median overall survival; multivariate analysis adjusted for these PFT results showed that high HRCT score was an independent risk factor for mortality, suggesting that HRCT findings can better reflect the severity of lung involvement in patients with pSS.
There are some limitations in this study. First, patients without pulmonary symptoms were not included. Second, this is not a prospective study. Furthermore, another limitation was the small sample size.
In conclusion, the presence of lung involvement with a high HRCT score or poor PFT was determined to be a risk factor for mortality in patients with pSS in Taiwan.
